Skip to main content

Advertisement

Table 3 Domain ratings between patient subgroups

From: Patients and surgeons provide endorsement of core domains for total joint replacement clinical trials

  Male Female Age < 55 years Age ≥ 55 years OA RA THR TKR
Core domains
 Joint pain 8 (7–9) 9 (8–9) 9 (7–9) 9 (8–9) 9 (8–9) 9 (7–9) 9 (8–9) 9 (7–9)
***    **
 Function 9 (8–9) 9 (8–9) 9 (8–9) 9 (8–9) 9 (8–9) 9 (8–9) 9 (8–9) 9 (8–9)
*** * *  
 Patient satisfaction 8 (8–9) 9 (8–9) 9 (8–9) 9 (8–9) 9 (8–9) 8 (8–9) 9 (8–9) 8 (8–9)
***    ***
 Revision surgery 7 (4–9) 8 (5–9) 7 (5–9) 8 (5–9) 8 (5–9) 7 (5–9) 8 (5–9) 7 (5–9)
***    
 Adverse events 8 (6–9) 9 (7–9) 8 (7–9) 8 (7–9) 8 (7–9) 8 (5–9) 8 (7–9) 8 (6–9)
***    
 Death 9 (5–9) 9 (6–9) 9 (6–9) 9 (6–9) 9 (6–9) 8 (6–9) 9 (7–9) 9 (5–9)
***    *
Additional domains         
 Cost 7 (5–8) 7 (5–9) 7 (5–8) 7 (5–8) 7 (5–8) 7 (5–9) 7 (5–8) 7 (5–8)
*** *   
 Patient participation 7 (6–9) 8 (7–9) 8 (6–9) 8 (6–9) 8 (6–9) 8 (7–9) 8 (6–9) 8 (6–9)
***    
  1. Abbreviations: OA Osteoarthritis, RA Rheumatoid arthritis, THR Total hip replacement, TKR Total knee replacement
  2. Significant p values are denoted as follows: * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001. Blank values underneath each pair of median (IQR) indicate no statistical significance. Each domain was rated on a 1–9 scale, with 1–3 indicating limited or no importance for patients, 4–6 being important but not critical, and 7–9 being critical